These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28321924)

  • 1. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
    Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
    Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
    Stamatoullas A; Rezine I; Mareschal S; Ménard AL; Lanic H; David M; Daliphard S; Penther D; Lemasle E; Cassuto O; Lenain P; Contentin N; Lepretre S; Jardin F; Bastard C; Tilly H
    Leuk Lymphoma; 2016; 57(6):1491-3. PubMed ID: 26430832
    [No Abstract]   [Full Text] [Related]  

  • 3. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for the treatment of myelodysplastic syndrome.
    Cataldo VD; Cortes J; Quintás-Cardama A
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine: in myelodysplastic syndromes.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
    Becherer K; Golda N; Feldman M; Diaz-Arias A; Caldwell C
    J Cutan Pathol; 2009 Sep; 36(9):1024-6. PubMed ID: 19674208
    [No Abstract]   [Full Text] [Related]  

  • 9. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
    Cseh AM; Niemeyer CM; Yoshimi A; Catala A; Frühwald MC; Hasle H; van den Heuvel-Eibrink MM; Lauten M; De Moerloose B; Smith OP; Bernig T; Gruhn B; Kulozik AE; Metzler M; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Br J Haematol; 2016 Mar; 172(6):930-6. PubMed ID: 26766110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 13. Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.
    Breccia M; Molica M; Zacheo I; Alimena G
    Expert Opin Pharmacother; 2014 Aug; 15(11):1621-30. PubMed ID: 24989987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
    Trubiano JA; Dickinson M; Thursky KA; Spelman T; Seymour JF; Slavin MA; Worth LJ
    Leuk Lymphoma; 2017 Oct; 58(10):2379-2386. PubMed ID: 28278704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
    Lee JH; Lee KH; Lee JH; Kim DY; Kim SH; Lim SN; Kim SD; Choi Y; Lee SM; Lee WS; Choi MY; Joo YD
    Leuk Res; 2011 Apr; 35(4):499-503. PubMed ID: 20674021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
    Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
    Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
    Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.